Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Mediwound Ltd MDWD

Healthcare
Mediwound Ltd is an Israel-based biopharmaceutical company that develops, manufactures and commercializes novel, cost effective, bio-therapeutic solutions for tissue repair and regeneration. Company's portfolio is focused on next-generation protein-based therapies for burn and wound care and tissue repair and includes products such as, NexoBrid, a concentrate of proteolytic enzymes enriched in... see more

Recent & Breaking News (NDAQ:MDWD)

MediWound to Report Third Quarter 2024 Financial Results

GlobeNewswire 12 days ago

MediWound Announces Phase II Head-to-Head Study Evaluating EscharEx® vs. Collagenase in Patients with Venous Leg Ulcers

GlobeNewswire October 10, 2024

MediWound to Participate in the 2024 Maxim Healthcare Virtual Summit

GlobeNewswire October 8, 2024

MediWound to Present at the H.C. Wainwright 26th Annual Global Investment Conference

GlobeNewswire September 3, 2024

MediWound Announces U.S. Food and Drug Administration Approval of NexoBrid® for the Treatment of Pediatric Patients with Severe Thermal Burns

GlobeNewswire August 15, 2024

MediWound Reports Second Quarter 2024 Financial Results and Provides Company Update

GlobeNewswire August 14, 2024

MediWound Announces Positive Results from the U.S. NexoBrid® Expanded Access Protocol (NEXT)

GlobeNewswire August 5, 2024

MediWound to Report Second Quarter 2024 Financial Results

GlobeNewswire August 2, 2024

MediWound Announces Publication of the EscharEx® Phase II ChronEx Study Results for Venous Leg Ulcers

GlobeNewswire July 29, 2024

MediWound Announces €16.25 Million Funding from the European Innovation Council Accelerator Program

GlobeNewswire July 16, 2024

Mölnlycke® Health Care announces US $15m investment in next-generation enzymatic therapeutics company MediWound Ltd

PR Newswire July 15, 2024

MediWound Announces $25 Million Strategic Private Placement Financing

GlobeNewswire July 15, 2024

MediWound Reports First Quarter 2024 Financial Results and Provides Company Update

GlobeNewswire May 29, 2024

MediWound to Report First Quarter 2024 Financial Results

GlobeNewswire May 22, 2024

MediWound to Present New Data from EscharEx® Phase II Studies at Three Leading Wound Care Conferences

GlobeNewswire April 25, 2024

MediWound Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Company Update

GlobeNewswire March 21, 2024

MediWound to Report Fourth Quarter and Full Year 2023 Financial Results

GlobeNewswire March 14, 2024

MediWound Announces Positive Results in Head-to-Head Comparison of EscharEx® vs. SANTYL® within the ChronEx Phase II Randomized Controlled Study

GlobeNewswire February 12, 2024

MediWound to Participate in Two Upcoming Investor Conferences

GlobeNewswire February 5, 2024

MediWound Announces that FDA has Accepted for Review the Supplement to the NexoBrid BLA to Include Pediatric Patients with Severe Thermal Burns

GlobeNewswire January 9, 2024